{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T23:44:55Z","timestamp":1709336695018},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,10,21]],"date-time":"2008-10-21T00:00:00Z","timestamp":1224547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s12072-008-9105-y","type":"journal-article","created":{"date-parts":[[2008,10,20]],"date-time":"2008-10-20T20:44:33Z","timestamp":1224535473000},"page":"440-456","source":"Crossref","is-referenced-by-count":11,"title":["A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B"],"prefix":"10.1007","volume":"2","author":[{"given":"Hie-Won","family":"Hann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki L.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith F.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,21]]},"reference":[{"key":"9105_CR1","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(03)15108-2","volume":"362","author":"C Lai","year":"2003","unstructured":"Lai C, Ratzui V, Yuen M-F, Poynard T. Viral hepatitis B. Lancet 2003;362:2089\u20132094","journal-title":"Lancet"},{"key":"9105_CR2","volume-title":"Hepatitis B","author":"World Health Organization","year":"2000","unstructured":"World Health Organization. Hepatitis B. Geneva: World Health Organization; 2000. Factsheet no. 204"},{"issue":"3","key":"9105_CR3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1155\/2007\/464652","volume":"18","author":"J Conly","year":"2007","unstructured":"Conly J, Johnston B. Treatment options for hepatitis B. Can J Infect Dis Med Microbiol 2007;18(3):173\u2013176","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"9105_CR4","first-page":"1887","volume":"88","author":"AM Di Bisceglie","year":"1993","unstructured":"Di Bisceglie AM, Fong TL, Fried MW, Swain MG, Baker B, Korenman J. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993;88:1887\u20131892","journal-title":"Am J Gastroenterol"},{"key":"9105_CR5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199008023230503","volume":"323","author":"RP Perrillo","year":"1990","unstructured":"Perrillo RP, Schiff ER, Davis GL, Bedenheimer HC, Lindsay K, Payne J. A randomised, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295\u2013301","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"9105_CR6","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/0168-8278(90)90175-Q","volume":"11","author":"V Perez","year":"1990","unstructured":"Perez V, Tanno H, Vilamil F, Fay O. Recombinant interferon alpha-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. J Hepatol 1990;11(Suppl):S113\u2013S117","journal-title":"J Hepatol"},{"key":"9105_CR7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(88)92355-0","volume":"2","author":"AS Lok","year":"1988","unstructured":"Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomized controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988;2:298\u2013302","journal-title":"Lancet"},{"key":"9105_CR8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2893.2007.00865.x","volume":"14","author":"L Lacey","year":"2007","unstructured":"Lacey L, Gane E. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepatitis 2007;14:751\u2013766","journal-title":"J Viral Hepatitis"},{"key":"9105_CR9","doi-asserted-by":"crossref","unstructured":"Liaw Y-F, Leung N, Kao J-H, Piratvisuth T, Gane E, Han K-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update [online]. Hepatol Int 2008. doi: 10.1007\/s12072-008-9080-3","DOI":"10.1007\/s12072-008-9080-3"},{"key":"9105_CR10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2893.2007.00902.x","volume":"15","author":"L Katz","year":"2008","unstructured":"Katz L, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008;15:89\u2013102","journal-title":"J Viral Hepat"},{"key":"9105_CR11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","volume":"339","author":"C-L Lai","year":"1998","unstructured":"Lai C-L, Chien R-N, Leung N, Chang T-T, Guan R, Tai D-I, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61\u201368","journal-title":"N Engl J Med"},{"key":"9105_CR12","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","volume":"341","author":"J Dienstag","year":"1999","unstructured":"Dienstag J, Schiff E, Wright T, Perrillo R, Han H-W, Goodman Z, et al. Lamivudine as initial treatment for CHB in the United States. N Engl J Med 1999;341:1256\u20131263","journal-title":"N Engl J Med"},{"key":"9105_CR13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.46.4.562","volume":"46","author":"S Schalm","year":"2000","unstructured":"Schalm S, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with CHB infection: a randomised trial. Gut 2000;46:562\u2013568","journal-title":"Gut"},{"key":"9105_CR14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0168-8278(03)00076-X","volume":"38","author":"E Schiff","year":"2003","unstructured":"Schiff E, Dienstag J, Karayalcin S, Grimm I, Perrillo R, Husa P, et al. Lamivudine and 24\u00a0weeks of lamivudine\/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818\u2013826","journal-title":"J Hepatol"},{"key":"9105_CR15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/368083","volume":"36","author":"C-L Lai","year":"2003","unstructured":"Lai C-L, Dienstag J, Schiff E, Leung N, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687\u2013696","journal-title":"Clin Infect Dis"},{"key":"9105_CR16","first-page":"391","volume":"61","author":"G Yao","year":"2000","unstructured":"Yao G. Management of hepatitis B in China. J Med Virol 2000;61:391\u2013397","journal-title":"J Med Virol"},{"key":"9105_CR17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/hep.510290321","volume":"29","author":"N Tassopoulos","year":"1999","unstructured":"Tassopoulos N, Volpes R, Pastore G, Heathcote J, Buti M, Goldin R, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889\u2013896","journal-title":"Hepatology"},{"issue":"22","key":"9105_CR18","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa012452","volume":"346","author":"M Jonas","year":"2002","unstructured":"Jonas M, Kelley D, Mizerski J, Badia I, Areias J, Schwarz K, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346(22):1706\u20131713","journal-title":"N Engl J Med"},{"issue":"26","key":"9105_CR19","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"G Lau","year":"2005","unstructured":"Lau G, Piratvisuth T, Luo K, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352(26):2682\u20132695","journal-title":"N Engl J Med"},{"issue":"12","key":"9105_CR20","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau G, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351(12):1206\u20131217","journal-title":"N Engl J Med"},{"key":"9105_CR21","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1440-1746.2006.04630.x","volume":"22","author":"A Thompson","year":"2006","unstructured":"Thompson A, Ayres A, Yuen L, Bartholomeusz A, Bowden D, Iser D, et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol 2006;22:1078\u20131085","journal-title":"J Gastroenterol Hepatol"},{"key":"9105_CR22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","volume":"129","author":"C-L Lai","year":"2005","unstructured":"Lai C-L, Leung N, Teo E-K, Tong M, Wong F, Hann H-W, et al. A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528\u2013536","journal-title":"Gastroenterology"},{"key":"9105_CR23","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","volume":"357","author":"C-L Lai","year":"2007","unstructured":"Lai C-L, Gane E, Liaw Y-F, Hsu C-W, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576\u20132588","journal-title":"N Engl J Med"},{"issue":"10","key":"9105_CR24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"T-T Chang","year":"2006","unstructured":"Chang T-T, Gish R, de Man R, Gadana A, Sollano J, Chao Y-C, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354(10):1001\u20131010","journal-title":"N Engl J Med"},{"issue":"10","key":"9105_CR25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"C-L Lai","year":"2006","unstructured":"Lai C-L, Shouval D, Lok A, Chang T-T, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354(10):1011\u20131020","journal-title":"N Engl J Med"},{"key":"9105_CR26","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","volume":"45","author":"J Hoofnagle","year":"2007","unstructured":"Hoofnagle J, Doo E, Liang T, Fleischer R, Lok A. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056\u20131075","journal-title":"Hepatology"},{"key":"9105_CR27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/viro.1997.8676","volume":"235","author":"S Gunther","year":"1997","unstructured":"Gunther S, Sommer G, Plikat U, Iwanska A, Wain-Hobson S, Will H, et al. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G to A hypermutation. Virology 1997;235:104\u2013108","journal-title":"Virology"},{"key":"9105_CR28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/135965350400900522","volume":"9","author":"S Locarnini","year":"2004","unstructured":"Locarnini S, Hatzakis A, Heathcote J, Keeffe E, Liang T, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antiviral Ther 2004;9:679\u2013693","journal-title":"Antiviral Ther"},{"key":"9105_CR29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","volume":"46","author":"A Lok","year":"2007","unstructured":"Lok A, Zoulim F, Locarnini S, Bartholomeusz A, Ghany M, Pawlotsky J-M, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254\u2013265","journal-title":"Hepatology"},{"issue":"9","key":"9105_CR30","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","volume":"48","author":"D Tenney","year":"2004","unstructured":"Tenney D, Levine S, Rose R, Walsh A, Weinheimer S, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48(9):3498\u20133507","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"9105_CR31","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/JCM.32.9.2088-2091.1994","volume":"32","author":"H Zaaijer","year":"1994","unstructured":"Zaaijer H, Ter Borg F, Cuypers H, Hermus M, Lelie P. Comparison of methods for detection of hepatitis B virus DNA. J Clin Microbiol 1994;32(9):2088\u20132091","journal-title":"J Clin Microbiol"},{"issue":"8","key":"9105_CR32","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1128\/JCM.37.8.2461-2465.1999","volume":"37","author":"S Ho","year":"1999","unstructured":"Ho S, Chan T, Cheng I, Lai K. Comparison of second-generation Digene hybrid capture assay with the branched-DNA assay for measurement of hepatitis B virus DNA in serum. J Clin Microbiol 1999;37(8):2461\u20132465","journal-title":"J Clin Microbiol"},{"issue":"15","key":"9105_CR33","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1093\/nar\/25.15.2979","volume":"25","author":"M Collins","year":"1997","unstructured":"Collins M, Irvine B, Tyner D, Fine E, Zayati C, Chang C-A, et al. A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules\/ml. Nucleic Acid Res 1997;25(15):2979\u20132984","journal-title":"Nucleic Acid Res"},{"key":"9105_CR34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1099\/jmm.0.05071-0","volume":"52","author":"S Ho","year":"2003","unstructured":"Ho S, Yam W-C, Leung E, Wong L-P, Leung J, Lai K-N, et al. Rapid quantification of hepatitis B virus DNA by real-time PCR using fluorescent hybridization probes. J Med Microbiol 2003;52:397\u2013402","journal-title":"J Med Microbiol"},{"issue":"1","key":"9105_CR35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10096-001-0648-2","volume":"21","author":"I Zanella","year":"2002","unstructured":"Zanella I, Rossini A, Domenighini D, Albertini A, Cariani E. Quantitative analysis of hepatitis B virus DNA by real-time amplification. Eur J Clin Microbiol Infect Dis 2002;21(1):22\u201326","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"9105_CR36","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/JCM.38.5.1977-1980.2000","volume":"38","author":"T Chen","year":"2000","unstructured":"Chen T, Luk J, Cheung S-T, Yu W-C, Fan S-T. Evaluation of quantitative PCR and branched-chain DNA assay for detection of hepatitis B virus DNA in sera from hepatocellular carcinoma and liver transplant patients. J Clin Microbiol 2000;38(5):1977\u20131980","journal-title":"J Clin Microbiol"},{"key":"9105_CR37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1423-0410.2001.00003.x","volume":"80","author":"J Saldanha","year":"2001","unstructured":"Saldanha J, Gerlich W, Lelie N, Dawson P, Heerman K, Heath A. An international collaborative study to establish a World Health Organization standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sanguinis 2001;80:63\u201371","journal-title":"Vox Sanguinis"},{"issue":"2","key":"9105_CR38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1128\/JCM.38.2.702-707.2000","volume":"38","author":"L Stuyver","year":"2000","unstructured":"Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000;38(2):701\u2013707","journal-title":"J Clin Microbiol"},{"key":"9105_CR39","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/gast.2000.8559","volume":"119","author":"Y Liaw","year":"2000","unstructured":"Liaw Y, Leung N, Chang T, Guan R, Tai D, Ng K, et al. Effects of extended lamivudine therapy in Asian patients with CHB. Gastroenterology 2000;119:172\u2013180","journal-title":"Gastroenterology"},{"key":"9105_CR40","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","volume":"33","author":"N Leung","year":"2001","unstructured":"Leung N, Lai C-L, Chang T-T, Guan R, Lee C-M, Ng K-Y, et al. Extended lamivudine treatment in patients with CHB enhances hepatitis B e antigen seroconversion rates: results after 3\u00a0years of therapy. Hepatology 2001;33:1527\u20131532","journal-title":"Hepatology"},{"issue":"3","key":"9105_CR41","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1128\/AAC.00833-06","volume":"51","author":"D Tenney","year":"2007","unstructured":"Tenney D, Rose R, Baldick C, Levine S, Pokornowski K, Walsh A, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51(3):902\u2013911","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"9105_CR42","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/S0168-8278(07)62379-4","volume":"46","author":"R Colonno","year":"2007","unstructured":"Colonno R, Rose R, Pokornowski K, Baldick C, Eggers B, Yu D, et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients [abstract]. J Hepatol 2007;46(1):S294. (abstract 781)","journal-title":"J Hepatol"},{"issue":"30","key":"9105_CR43","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.3748\/wjg.v13.i30.4085","volume":"13","author":"H Chae","year":"2007","unstructured":"Chae H, Hann H-W. Baseline HBV DNA is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007;13(30):4085\u20134090","journal-title":"World J Gastroenterol"},{"key":"9105_CR44","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2893.2005.00687.x","volume":"13","author":"Y Liaw","year":"2006","unstructured":"Liaw Y, Lee C, Chien R, Yeh C. Switching to adefovir monotherapy after emergence of lamivudine resistant mutations in patients with liver cirrhosis. J Viral Hepat 2006;13:250\u2013255","journal-title":"J Viral Hepat"},{"key":"9105_CR45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.21534","volume":"45","author":"I Rapti","year":"2007","unstructured":"Rapti I, Dimou E, Mitsoula P, Hadziyannis S. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307\u2013313","journal-title":"Hepatology"},{"key":"9105_CR46","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1053\/j.gastro.2007.08.079","volume":"133","author":"P Lampertico","year":"2007","unstructured":"Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445\u20131551","journal-title":"Gastroenterology"},{"key":"9105_CR47","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/hep.21546","volume":"26","author":"Y Liaw","year":"2007","unstructured":"Liaw Y. Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how? Hepatology 2007;26:266\u2013268","journal-title":"Hepatology"},{"key":"9105_CR48","unstructured":"Gane E. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B [online]. Hepatol Int 2008. doi: 10.1007s12072-008-9083-0"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-008-9105-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-008-9105-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-008-9105-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T23:02:34Z","timestamp":1709334154000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-008-9105-y"}},"subtitle":["Lamivudine resistance"],"short-title":[],"issued":{"date-parts":[[2008,10,21]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["9105"],"URL":"https:\/\/doi.org\/10.1007\/s12072-008-9105-y","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,21]]}}}